Axsome Therapeutics (AXSM) said Monday that it expects total product revenue of about $196 million for Q4, up 65% from a year earlier.

Analysts surveyed by FactSet expect Q4 revenue of $187.3 million.

Auvelity, a treatment for major depressive disorder, is expected to generate about $155.1 million in Q4 net product sales, the company said.

Analysts surveyed by FactSet are expecting $149 million in Q4 Auvelity sales.

Axsome shares were 0.9% higher in premarket trading.